Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Blackrock Inc (BLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Blackrock Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.1 (market cap $29.60B), while Blackrock Inc trades at $1,152.79 (market cap $177.92B). The key difference: Blackrock Inc is far larger — about 6× Alnylam Pharmaceuticals, Inc.'s market cap, and Blackrock Inc pays a 2% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BLK | |
|---|---|---|
Market Cap | $29.60B | $177.92B |
Sector | Health | Financials |
52-Week High | $491.22 | $1.20K |
52-Week Low | $205.48 | $922.90 |
Enterprise Value | $27.56B | $179.02B |
Volume | — | 641,547 |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
BLK trades at $1,131.40, down slightly by 0.44% today, with a bullish technical signal from moving averages and strong analyst support. The company reported revenue of $24.22 billion for 2025, with net income of $5.55 billion, and has consistently beaten EPS estimates in recent quarters. Recent news highlights BlackRock's involvement in a major AI financing initiative with Nvidia and other firms.
The outlook remains positive given strong earnings performance and a consensus buy rating from analysts, with a price target of $1,350. Key risks include potential legal challenges from investor lawsuits and volatile cash flow trends, but institutional confidence and strategic partnerships provide a solid foundation for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Blackrock Inc
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →
